Metformin is a novel suppressor for transforming growth factor (TGF)-β1

• Published in: Scientific reports 2016-06, Vol.6 (1), p.28597-28597, Article 28597
• Main Authors: Xiao, Han, Zhang, Jianshu, Xu, Zhonghe, Feng, Yenan, Zhang, Mingliang, Liu, Jianli, Chen, Ruifei, Shen, Jing, Wu, Jimin, Lu, Zhizhen, Fang, Xiaohong, Li, Jingyuan, Zhang, Youyi
• Format: Article
• Language: English
• Subjects: 119/118; 13; 13/1; 14/3; 14/35; 631/154/555; 639/624/1107/328/1262; 639/624/1107/328/2239; 692/4017; 82/103; 82/29; 96/63; Humanities and Social Sciences; multidisciplinary; Science
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/srep28597

Metformin is a widely used first-line antidiabetic drug that has been shown to protect against a variety of specific diseases in addition to diabetes, including cardiovascular disorders, polycystic ovary syndrome and cancer. However, the precise mechanisms underlying the diverse therapeutic effects of metformin remain elusive. Here, we report that transforming growth factor-β1 (TGF-β1), which is involved in the pathogenesis of numerous diseases, is a novel target of metformin. Using a surface plasmon resonance-based assay, we identified the direct binding of metformin to TGF-β1 and found that metformin inhibits [ 125 I]-TGF-β1 binding to its receptor. Furthermore, based on molecular docking and molecular dynamics simulations, metformin was predicted to interact with TGF-β1 at its receptor-binding domain. Single-molecule force spectroscopy revealed that metformin reduces the binding probability but not the binding force of TGF-β1 to its type II receptor. Consequently, metformin suppresses type II TGF-β1 receptor dimerization upon exposure to TGF-β1, which is essential for downstream signal transduction. Thus, our results indicate that metformin is a novel TGF-β suppressor with therapeutic potential for numerous diseases in which TGF-β1 hyperfunction is indicated.